Prescription medicine
Glucagon Brand names: Gvoke, Baqsimi
Glucagon (Baqsimi) is a prescription medicine with an FDA approval on record since 1960. FDA's NDC Directory lists it from 6 generic labelers, and pharmacies paid $154.20 per kit (Glucagon 1 mg emergency kit) in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the glucagon FDA label on DailyMed (effective August 11, 2026, Amphastar Pharmaceuticals, Inc.); the NDA 12122 record on Drugs@FDA; every glucagon label on DailyMed.
Highlights of the record
FDA label of August 11, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageGLUCAGON for Injection is an antihypoglycemic agent and a gastrointestinal motility inhibitor indicated: for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes.
Forms and strengths
- 3 mg
- 0.5 mg/.1ml
- 1 mg/.2ml
- 1 mg/ml
Kit; injection (solution); powder; injection (powder) (lyophilized) for solution.
On the market
- Earliest approval on file
- November 14, 1960 Glucagon, Lilly; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 4 first December 28, 2020; 4 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 10 of which 6 under generic applications, 6 under brand applications, repackagers included
- Last listed patent
- September 23, 2039 Baqsimi powder; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $154.20 per kit Glucagon 1 mg emergency kit
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 1 since 2026 0 Class I among all firms' recalls; latest June 23, 2026
- FAERS reports
- 4,129 through July 30, 2026
What is glucagon used for?
From the label: indications and usageGLUCAGON for Injection is an antihypoglycemic agent and a gastrointestinal motility inhibitor indicated: for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes. ( 1.1 ) as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients. ( 1.2 ) 1.1 Severe Hypoglycemia Glucagon for Injection is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus. 1.2 Diagnostic Aid Glucagon for Injection is indicated as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.
FDA pharmacologic class: Antihypoglycemic Agent and Gastrointestinal Motility Inhibitor.
Source: FDA drug label (Glucagon), Amphastar Pharmaceuticals, Inc., effective August 11, 2026 (SPL set 8cc40354-b5ac-45b6-a211-93b44444f2a3), via openFDA; the full label on DailyMed
Is there a generic for glucagon (Baqsimi)?
The FDA approved the first generic glucagon on December 28, 2020. 4 generic applications are approved; 4 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists glucagon from 6 labelers under a generic (ANDA) application and from 6 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists 3 patents for Baqsimi powder, the last expiring on September 23, 2039. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 1960 earliest approval on file
- 2020 first generic approved
- 2039 last listed patent
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for glucagon (Baqsimi)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $154.20 per kit (Glucagon 1 mg emergency kit), down 31% from $223.39 on October 8, 2025. The survey records the price, not the reason for a change; large moves often follow a new generic or a list-price change. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Glucagon 1 mg emergency kit (generic)
- Glucagon 1 mg emergency kit (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Glucagon 1 mg emergency kit | Generic | $154.20 per kit | n/a | -31% |
| Baqsimi 3 mg spray one pack | Brand | $292.98 per unit | n/a | +3% |
| Baqsimi 3 mg spray two pack | Brand | $293.04 per unit | n/a | +3% |
| Glucagon 1 mg emergency kit | Brand | $240.40 per kit | n/a | +0.3% |
| Gvoke 1 mg/0.2 mL kit | Brand | $1,600.99 per mL | n/a | +3% |
| Gvoke hypopen 1-pk 1 mg/0.2 mL | Brand | $1,603.18 per mL | n/a | +3% |
| Gvoke hypopen 2-pk 1 mg/0.2 mL | Brand | $1,596.19 per mL | n/a | +3% |
| Gvoke hypopen 2pk 0.5 mg/0.1 mL | Brand | $3,202.33 per mL | n/a | +3% |
| Gvoke pfs 1-pk 1 mg/0.2 mL syringe | Brand | $1,600.96 per mL | n/a | +3% |
| Gvoke pfs 2-pk 1 mg/0.2 mL syringe | Brand | $1,604.34 per mL | n/a | +2% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has glucagon been recalled?
The FDA's Enforcement Report lists 1 recall naming glucagon since 2026: 0 Class I (the most serious), 1 Class II, 0 Class III; 1 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| June 23, 2026 | Class II | Lupin Pharmaceuticals Inc. | CGMP deviation: OOS result observed for the Gliding Force functionality test during 12-month long term stability testing. |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the glucagon label say about other medicines?
The glucagon label names 3 other medicines in its interaction, contraindication or warning sections. The labels of 18 other medicines name glucagon. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Indomethacin | drug interactions | Clinical Impact: In patients taking indomethacin, Glucagon for Injection may lose its ability to raise blood glucose or may even produce hypoglycemia. Intervention: Monitor blood glucose levels during glucagon treatment of patients taking indomethacin. |
| Phentolamine | warnings and precautions | If the patient develops a substantial increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure. |
| Warfarin | drug interactions | Clinical Impact: Glucagon for Injection may increase the anticoagulant effect of warfarin. Intervention: Monitor patients for unusual bruising or bleeding, as adjustments in warfarin dosage may be required. |
Other labels that name glucagon
Source: FDA drug label (Glucagon), Amphastar Pharmaceuticals, Inc., effective August 11, 2026 (SPL set 8cc40354-b5ac-45b6-a211-93b44444f2a3), via openFDA; the full label on DailyMed
What do FAERS reports show for glucagon?
The FDA Adverse Event Reporting System holds 4,129 reports that list glucagon among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 669 are coded as a death and 1,990 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other antihypoglycemic agents
- the pharmacologic class, with prices and generics
- Glucagon side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other